Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia

被引：1
|
作者：
Kurtz, Stephen E. [1 ,2 ]
Eide, Christopher A. [1 ]
Kaempf, Andy [3 ]
Long, Nicola [1 ]
Agarwal, Anupriya [1 ]
Tognon, Cristina E. [1 ]
Mori, Motomi [3 ]
Druker, Brian J. [1 ]
Tyner, Jeffrey W. [4 ]
机构：
[1] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Mail Code KR HEM, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Mail Code KR HEM, Portland, OR 97201 USA
[3] Oregon Hlth & Sci Univ, Knight Canc Inst, Biostat Shared Resource, Portland, OR 97201 USA
[4] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-126020
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
878
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations
    Shahswar, Rabia
    Ganser, Arnold
    EXPERT REVIEW OF HEMATOLOGY, 2024, 17 (10) : 723 - 739
  • [22] Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America
    Gomez-De Leon, Andres
    Demichelis-Gomez, Roberta
    Pinedo-Rodriguez, Alfredo
    Enriquez-Vera, Daniel
    Flores-Jimenez, Juan Antonio
    Ceballos-Lopez, Adrian Alejandro
    Rodriguez-Mejorada, Margarita
    Herrera Riojas, Miguel Angel
    Ovilla-Martinez, Roberto
    Baez-Islas, Pamela
    Cota-Rangel, Xochitl
    Neme-Yunes, Yvette
    Inclan-Alarcon, Sergio
    Lopez-Flores, Nelson J.
    Colunga-Pedraza, Perla R.
    Rodriguez-Zuniga, Anna C.
    Gomez-Almaguer, David
    HEMATOLOGY, 2022, 27 (01) : 249 - 257
  • [23] Combined venetoclax and alvocidib in acute myeloid leukemia
    Bogenberger, James
    Whatcott, Clifford
    Hansen, Nanna
    Delman, Devora
    Shi, Chang-Xin
    Kim, Wontak
    Haws, Hillary
    Soh, Katherine
    Lee, Ye Sol
    Peterson, Peter
    Siddiqui-Jain, Adam
    Weitman, Steven
    Stewart, Keith
    Bearss, David
    Mesa, Ruben
    Warner, Steven
    Tibes, Raoul
    ONCOTARGET, 2017, 8 (63): : 107206 - 107222
  • [24] Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia
    DiNardo, Courtney D.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 82 - 83
  • [25] Personalized Drug Combinations for the Treatment of Acute Myeloid Leukemia (AML) Patients
    Kang, Yunyi
    Tran, Trish
    Zhang, Linda
    Ball, Edward D.
    Piermarocchi, Carlo
    Paternostro, Giovanni
    BLOOD, 2014, 124 (21)
  • [26] Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia
    Mason-Osann, Emily
    Pomeroy, Amy E.
    Palmer, Adam C.
    Mettetal, Jerome T.
    BLOOD CANCER DISCOVERY, 2024, 5 (02): : 95 - 105
  • [27] Synergistic drug combinations promote the development of resistance in acute myeloid leukemia
    Mason-Osann, Emily
    Pomeroy, Amy E.
    Palmer, Adam C.
    Mettetal, Jerome T.
    CANCER RESEARCH, 2023, 83 (07)
  • [28] Patterns of Venetoclax Sensitivity in Chronic Lymphocytic Leukemia
    Dibb, James T.
    Long, Nicola
    Eide, Christopher A.
    Kurtz, Stephen E.
    Tognon, Cristina E.
    Tyner, Jeffrey W.
    Druker, Brian J.
    BLOOD, 2020, 136
  • [29] Prediction of Volasertib Sensitivity in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax Plus Azacitidine
    Patil, Lokesh
    Gu, Christine J.
    Tognon, Cristina
    Long, Nicola
    Johnson, Kara
    Fischer, Melissa A.
    Ball, Somedeb
    Savona, Michael R.
    Leonardi, Chris
    Wagner, Joseph
    Michelson, Glenn
    Lacher, Markus D.
    BLOOD, 2024, 144 : 5818 - 5819
  • [30] Acid ceramidase inhibition enhances venetoclax sensitivity in preclinical models of acute myeloid leukemia
    Ung, Johnson
    Tan, Su-Fern
    Shaw, Jeremy J.
    Fox, Todd E.
    Taori, Maansi
    Claxton, David F.
    Fisher-Wellman, Kelsey H.
    Cabot, Myles C.
    Feith, David J.
    Loughran, Thomas P.
    CANCER RESEARCH, 2024, 84 (06)
12345